文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.

作者信息

Reynolds Gemma K, Maclean Marsali, Cliff Edward R Scheffer, Teh Benjamin W, Thursky Karin A, Slavin Monica A, Anderson Mary Ann, Hawkes Eliza A

机构信息

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.

出版信息

Blood Adv. 2024 Jul 9;8(13):3555-3559. doi: 10.1182/bloodadvances.2024012916.

DOI:10.1182/bloodadvances.2024012916
PMID:38625983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261259/
Abstract
摘要

相似文献

[1]
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.

Blood Adv. 2024-7-9

[2]
[Bispecific antibodies in onco-hematology: Applications and perspectives].

Bull Cancer. 2021-10

[3]
Current landscape of CD3 bispecific antibodies in hematologic malignancies.

Trends Cancer. 2024-8

[4]
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma.

Am Soc Clin Oncol Educ Book. 2024-6

[5]
Blinatumomab significantly improves overall survival.

Lancet Oncol. 2017-4

[6]
Phase 1/2 study of blinatumomab in relapsed paediatric ALL.

Lancet Oncol. 2016-12

[7]
Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.

Leuk Lymphoma. 2018-7

[8]
The value of bispecific antibodies in relapsed and refractory DLBCL.

Leuk Lymphoma. 2024-6

[9]
Cancer immune therapy for lymphoid malignancies: recent advances.

Semin Immunopathol. 2018-7-13

[10]
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Blood Cancer J. 2018-8-22

引用本文的文献

[1]
Infectious Complications in Patients with B-Cell Non-Hodgkin Lymphoma Treated with Bispecific Antibodies.

Cancers (Basel). 2025-7-22

[2]
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects.

Hematol Oncol. 2025-6

[3]
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

Cancers (Basel). 2025-5-8

[4]
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Blood Adv. 2025-8-26

[5]
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.

J Pers Med. 2025-1-28

[6]
Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances.

Korean J Intern Med. 2025-5

[7]
New bispecific antibodies in diffuse large B-cell lymphoma.

Haematologica. 2025-7-1

[8]
Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review.

Viruses. 2025-1-18

[9]
Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient.

IDCases. 2024-12-22

[10]
Bispecific antibodies in follicular lymphoma.

Haematologica. 2025-7-1

本文引用的文献

[1]
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.

Clin Lymphoma Myeloma Leuk. 2024-4

[2]
Lifting of Embargoes to Data Sharing in Clinical Trials Published in Top Medical Journals.

JAMA. 2024-1-23

[3]
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.

Nat Med. 2024-1

[4]
Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.

Open Forum Infect Dis. 2023-11-2

[5]
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.

Haematologica. 2024-4-1

[6]
Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis.

Crit Rev Oncol Hematol. 2023-12

[7]
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients.

Lancet Infect Dis. 2024-1

[8]
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.

Blood Adv. 2023-10-24

[9]
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.

Blood Adv. 2023-10-10

[10]
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

J Clin Oncol. 2023-4-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索